CClinicalTrials.gg
CompletedNCT02272244Updated May 4, 2025Results posted

Increasing Colorectal Cancer (CRC) Screening Among Hispanic Primary Care Patients

An interventional study of Decision Support & Navigation and Standard in Colorectal Cancer, sponsored by Thomas Jefferson University. Completed at 3 sites in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

This study is designed to test a standard mailed intervention (SI) versus a novel decision support and navigation intervention (DSNI). Working with patients and stakeholders, this randomized trial will include 400 Hispanic men and women who are 50 to 75 years of age, patients in community based primary care practices, and are eligible for CRC screening. We will consent, survey, and randomize participants either to the SI Group (n=200) or the DSNI Group (n=200). Study specific aims are to: (1) Assess intervention (DSNI versus SI) impact on overall CRC screening adherence; (2)Assess intervention (DNSI versus SI) impact on CRC screening decision stage; (3) Assess intervention (DNSI versus SI) impact on test-specific CRC screening adherence; and (4) Assess intervention (DNSI versus SI) impact on CRC and knowledge and perceptions.

02

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Cancer Screening
  • Decision Support
  • Navigation
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's enrollment of 400 is above the median of 77 across 4,123 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Thomas Jefferson University is the lead sponsor of 384 studies on the registry; 71 are open to participants now.

Of its 44 completed or terminated interventional studies of FDA-regulated products, 20 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or Female
  • Self-identifies as being Hispanic or Latino
  • 50 to 75 years of age

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of CRC
  • Up to date with CRC screening guidelines.
  • Personal history of inflammatory bowel disease
  • Personal history of polyps
  • Family history of CRC diagnosed before the age of 60 years
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Active comparator
    Standard

    SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.

    Behavioral: Standard

  • Experimental
    Decision Support & Navigation

    DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.

    Behavioral: Decision Support & Navigation

Interventions

  • BehavioralDecision Support & Navigation
  • BehavioralStandard
06

What researchers measure

Primary outcomes

  1. Overall Screening Adherence

    The two study groups will be compared in terms of the fraction of participants who undergo CRC screening (through SBT, colonoscopy, flexible sigmoidoscopy, etc.) within 12 months of the randomization date. Screening will be measured using data from the 6-month survey and the 12-month chart audit.

    Time frame: 12 months

Secondary outcomes

  1. Change in Screening Decision Stage

    At baseline and endpoint (6-month) survey, participants were asked about their decision stage regarding CRC screening. Possible decision stages are, ranked from lowest to highest stage: Decided not to do, Not considering, Haven't decided, Decided to Do and Done, with "Done" only possible at endpoint.

    Time frame: 6 months

  2. Test Specific Screening Adherence

    Test adherence (SBT or endoscopy) will be assessed using 6-month survey and 12-month medical records data. The two study groups will be compared in terms of the fraction of participants who have a screening test within 12 months.

    Time frame: 12 Months

  3. Screening Knowledge and Perceptions

    Knowledge and perceptions (Preventive Health Model scales) about CRC and screening will be assessed in a 6-month survey. Knowledge was measured by a set of 10 true-false statements about CRC and CRC screening. Knowledge was scored as the number of items correct with a possible range of 0 to 10. Perceptions about CRC and screening were measured using a 20-item scale based on the Preventive Health Model. Items were measured on a 5 point Likert scale ranging from 1 = Strongly Disagree to 5 = Strongly Agree. The total score and subscale scores were computed by taking the mean of component items resulting in scores that could range from 1 to 5, with higher scores indicating more favorable attitudes towards the CRC screening preventive health behavior.

    Time frame: 6 months

07

Results

Posted Aug 12, 2019

Participant flow

2,720 study invitation letters sent to subjects from 5 practices that appeared to meet eligibility criteria based on medical records.

Participant flow — Overall Study
MilestoneStandardDecision Support & Navigation
Started203197
Completed203197
Not completed00

Outcome measures

PrimaryOverall Screening Adherence

The two study groups will be compared in terms of the fraction of participants who undergo CRC screening (through SBT, colonoscopy, flexible sigmoidoscopy, etc.) within 12 months of the randomization date. Screening will be measured using data from the 6-month survey and the 12-month chart audit.

Time frame:
12 months
Reported as:
Count of participants · Participants
Overall Screening Adherence
ParticipantsStandardDecision Support & Navigation
Screened88153
Not Screened11544
Statistical analysis
  • Standard vs Decision Support & Navigation · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.83 · 95% CI 3.08 to 7.58Model adjusted for age, sex, practice, baseline preferred test and baseline overall decision stage
SecondaryChange in Screening Decision Stage

At baseline and endpoint (6-month) survey, participants were asked about their decision stage regarding CRC screening. Possible decision stages are, ranked from lowest to highest stage: Decided not to do, Not considering, Haven't decided, Decided to Do and Done, with "Done" only possible at endpoint.

Time frame:
6 months
Reported as:
Count of participants · Participants
Change in Screening Decision Stage
ParticipantsStandardDecision Support & Navigation
Forward Change6197
No Change5223
Backward Change103
Statistical analysis
  • Standard vs Decision Support & Navigation · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.91 · 95% CI 2.55 to 9.47Model compares Forward Change to No Change or Backwards Change and is adjusted for all baseline covariates.
SecondaryTest Specific Screening Adherence

Test adherence (SBT or endoscopy) will be assessed using 6-month survey and 12-month medical records data. The two study groups will be compared in terms of the fraction of participants who have a screening test within 12 months.

Time frame:
12 Months
Reported as:
Count of participants · Participants
Test Specific Screening Adherence
ParticipantsStandardDecision Support & Navigation
None11544
Stool Blood Test76113
Colonoscopy1240
Statistical analysis
  • Standard vs Decision Support & Navigation · Regression, Multinomial · p = <0.001Model compared rates of SBT, CX and none; model is adjusted for age, sex, practice, baseline preferred test and baseline overall decision stage
  • Standard vs Decision Support & Navigation · Odds Ratio (OR) · p = 0.001 · Odds ratio (or): 4.20 · 95% CI 2.63 to 6.70Stool Blood Test vs None
  • Standard vs Decision Support & Navigation · Odds Ratio (OR) · p = 0.001 · Odds ratio (or): 8.79 · 95% CI 4.13 to 18.74
SecondaryScreening Knowledge and Perceptions

Knowledge and perceptions (Preventive Health Model scales) about CRC and screening will be assessed in a 6-month survey. Knowledge was measured by a set of 10 true-false statements about CRC and CRC screening. Knowledge was scored as the number of items correct with a possible range of 0 to 10. Perceptions about CRC and screening were measured using a 20-item scale based on the Preventive Health Model. Items were measured on a 5 point Likert scale ranging from 1 = Strongly Disagree to 5 = Strongly Agree. The total score and subscale scores were computed by taking the mean of component items resulting in scores that could range from 1 to 5, with higher scores indicating more favorable attitudes towards the CRC screening preventive health behavior.

Time frame:
6 months
Reported as:
Mean · units on a scale
Screening Knowledge and Perceptions
units on a scaleStandardDecision Support & Navigation
Preventive Health Model (PHM)3.8 ± 0.53.8 ± 0.6
PHM: Salience4.8 ± 0.54.7 ± 0.6
PHM: Response Efficacy4.5 ± 0.74.5 ± 0.7
PHM: Susceptibility2.6 ± 1.02.8 ± 1.0
PHM: Worries and Concerns3.1 ± 1.13.1 ± 1.1
PHM: Social Support and Influence4.4 ± 0.84.4 ± 0.9
Knowledge Test4.7 ± 1.84.6 ± 2.1
Statistical analysis
  • Standard vs Decision Support & Navigation · Regression, Linear · p = 0.862 · Mean difference (final values): -0.01 · 95% CI -0.15 to 0.13Model compares DSNI to SI.
  • Standard vs Decision Support & Navigation · Regression, Linear · p = 0.880 · Mean difference (final values): 0.04 · 95% CI -.47 to .55Model compares DSNI to SI.

Adverse events

Collected over 1 Year from baseline. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard0/203 (0%)0/203 (0%)0/203 (0%)
Decision Support & Navigation0/197 (0%)0/197 (0%)0/197 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)StandardDecision Support & NavigationTotal
Mean57.5 ± 6.557.2 ± 6.457.3 ± 6.5
Age, Customized
Age, Customized(Participants)StandardDecision Support & NavigationTotal
Age (years) — 50-59140137277
Age (years) — 60-69474895
Age (years) — 70-79161228
Sex: Female, Male
Sex: Female, Male(Participants)StandardDecision Support & NavigationTotal
Female118117235
Male8580165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)StandardDecision Support & NavigationTotal
Race — White/Caucasian6469133
Race — Black/African American6157118
Race — Other424991
Race — Unknown/Not Reported362258
Marital Status
Marital Status(Participants)StandardDecision Support & NavigationTotal
Married9478172
Living as marreid101020
Divorced252651
Separated201333
Widowed71724
Never married4753100
Education
Education(Participants)StandardDecision Support & NavigationTotal
Less than HS90102192
HS/GED5851109
Completed Non-College/Business/Trade/Tech13821
2-yr Associates161935
College Degree and above261743
Employment Status
Employment Status(Participants)StandardDecision Support & NavigationTotal
Working full-time444185
Working part-time413576
Keeping House454590
Unable to Work/Disability5362115
Retired201434
Family Income
Family Income(Participants)StandardDecision Support & NavigationTotal
Under $14,999144136280
$15,000-$29,000374582
$30,000-$45,999181230
$46,000-$59,999347
Unknown/Not Reported101

9 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18105, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19012, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

Publications

  • Myers RE, Stello B, Daskalakis C, Sifri R, Gonzalez ET, DiCarlo M, Johnson MB, Hegarty SE, Shaak K, Rivera A, Gordils-Molina L, Petrich A, Careyva B, de-Ortiz R, Diaz L. Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients. Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):384-391. doi: 10.1158/1055-9965.EPI-18-0260. Epub 2018 Oct 17. PubMed 30333221 ↗

Study documents

  • Protocol and statistical analysis plan · Dec 14, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02272244
Lead sponsor
Thomas Jefferson University
Collaborators
Lehigh Valley Hospital, Fox Chase Cancer Center, Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Oct 22, 2014
Start date
Oct 1, 2014
Primary completion
Jan 20, 2017
Completion
Mar 31, 2017
Results posted
Aug 12, 2019
Last update
May 4, 2025

Study contacts

Ronald E Myers, PhD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion